Yüklüyor......

Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ERJ Open Res
Asıl Yazarlar: Deterding, Robin, Griese, Matthias, Deutsch, Gail, Warburton, David, DeBoer, Emily M., Cunningham, Steven, Clement, Annick, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Voss, Florian, Schmid, Ulrike, Schlenker-Herceg, Rozsa, Verri, Daniela, Dumistracel, Mihaela, Schiwek, Marilisa, Stowasser, Susanne, Tetzlaff, Kay, Clerisme-Beaty, Emmanuelle, Young, Lisa R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: European Respiratory Society 2021
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215331/
https://ncbi.nlm.nih.gov/pubmed/34164554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00805-2020
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!